

To whom it may concern

Bonn, 31. Oktober 2023

Universitätsklinikum Bonn
Studienzentrale – SZB
Institut für Klinische Chemie und
Pharmakologie
Venusberg-Campus 1
53127 Bonn

Tel.: 0228. 287-16046
Fax: 0228. 287-16039

Titel: Efficacy of ruxolitinib cream in Prurigo nodularis patients: A randomized, placebo-controlled pilot study
Short title: PRUX
EudraCT-Nr.: 2019-004739-22
Trialcode: DER-201805

Studienzentrale-SZB@ukbonn.de
www.studienzentrum-bonn.de

The clinical trial entitled "Efficacy of ruxolitinib cream in prurigo nodularis patients: A randomized, placebo-controlled pilot study" never started. Reason is a missing clearance from the sponsor (Rheinische Friedrich-Wilhelms-University of Bonn, represented by the Medical Faculty of the University of Bonn, represented by the Dean of the Medical Faculty, Venusberg-Campus 1, 53127 Bonn, Germany). According to the processes for the sponsor in Bonn this clearance is needed for any trial related activities.

The above mentioned clearance could not be granted due to missing contractual agreements between the sponsor and the manufacturer regarding manufacturing responsibilities (Quality Agreement in regards to Good Manufacturing Practice). Despite extensive contract negotiations an agreement between sponsor and manufacturer could never be reached.

The clinical trial was deregistered for the aforementioned reason prior to the start of recruitment.

No patients have been or will be enrolled at the trial site for this clinical trial. (Clinic and Polyclinic for Dermatology and Allergology, University Hospital Bonn).

Therefore, the start of the clinical trial was never reported and the responsible ethics committee as well as all involved authorities were informed in a timely manner respectively.

For the above mentioned reasons the Trial Status: "Completed" is not correct and should be: "Trial not started".

Unfortunately, the entry in the EU Register cannot be changed. For this reason, this explanation serves as a supplement.